Clinical Trials
Aduro’s lead program, a combination immunotherapy comprised of its novel GVAX Pancreas and CRS-207 technologies, is being evaluated in a 240-patient Phase 2b ECLIPSE trial in patients with metastatic pancreatic cancer.

Aduro is harnessing the immune system to treat cancer.  Aduro's technologies are designed to activate both innate and adaptive immunity to generate a potent and long-lasting response against cancer.   

  • October, 30 2014  | 5 Lifesaving Medical Breakthroughs (see #2)  READ IT HERE
  • October, 23 2014  | Aduro presents updated interim results from Phase 1b clinical trial in mesothelioma at International Mesothelioma Interest Group Conference  READ IT HERE
  • October, 16 2014  | Aduro expands collaboration with Johnson & Johnson Innovation and Janssen for lung cancer immunotherapies  READ IT HERE
  • October, 15 2014  | Aduro BioTech announces interim Phase 1B clinical data of CRS-207 for the treatment of mesothelioma accepted for oral presentation at the International Mesothelioma Interest Group conference  READ IT HERE
  • October, 09 2014  | Aduro BioTech’s Chief Scientific Officer, Thomas W. Dubensky, Jr., Ph.D., a featured speaker on action of vaccine adjuvants at Keystone Symposia  READ IT HERE
  • September, 22 2014  | Aduro BioTech named one of Fierce 15 leading biotech companies in 2014  READ IT HERE
Copyright 2011-2013 Aduro Biotech. All rights reserved.
Privacy Policy  |  Terms of Use